edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Basilea Pharmaceutica
Basilea Pharmaceutica is focused on treating infectious diseases; its marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.
Basilea Pharmaceutica — 12 videos in collection
Basilea Pharmaceutica is a Switzerland-based, commercial-stage biotech focused on treating infectious diseases. Its marketed products, Cresemba (an antifungal) and Zevtera (an anti-MRSA broad-spectrum antibiotic), are therapeutic agents against severe infection including drug-resistant strains of bacteria (eg MRSA) or fungi. The company continues to innovate to address unmet medical needs, leveraging management’s strong expertise in antifungals and antibiotics.
In this interview, CEO David Veitch provides a recap of the company’s ongoing efforts and pipeline.
Get access to the very latest content matched to your personal investment style.